A new imaging test for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a special imaging dye that targets a protein called BCMA on multiple myeloma cells. It may help doctors see and diagnose the disease more clearly during bone marrow or tissue biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have suspected or confirmed multiple myeloma.
- You need to be scheduled for a bone marrow or tissue biopsy within the next 3 months.
- You must be willing to give written consent and cooperate with the procedure.
- You cannot be pregnant.
- You must understand the examination process.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
This study tests a new imaging method that uses a special tracer to find multiple myeloma cells in the body. It may help doctors see the disease more clearly and guide treatment.
This study uses a special PET scan to look for multiple myeloma in your body. It may help doctors see where the disease is and how active it is.
This trial uses a new radioactive tracer that attaches to a protein found on many solid tumors, allowing doctors to see tumors on a PET scan. It may help improve how tumors are detected and monitored.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
Hear when a new Multiple Myeloma and Malignant Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.